Abbott Labs

ABT-N

NYSE:ABT

84.95
3.02 (3.69%)
Abbott Laboratories is a multinational health care company with headquarters in Lake Bluff, Illinois.
More at Wikipedia

Analysis and Opinions about ABT-N

Signal
Opinion
Expert
PAST TOP PICK
PAST TOP PICK
January 14, 2020
(A Top Pick Jan 10/19, Up 25%) A diversified healthcare company that's done well. They sell generic drugs to higher-growth EM (40% of revenues); adult and child nutritional products; and medical products which is showing profit momentum driven by product launches. Aging demographics favour ABT. They don't suffer US drug pricing issues, either. They've increased their dividend for the last 47 years.
Show full opinionHide full opinion
Abbott Labs (ABT-N)
January 14, 2020
(A Top Pick Jan 10/19, Up 25%) A diversified healthcare company that's done well. They sell generic drugs to higher-growth EM (40% of revenues); adult and child nutritional products; and medical products which is showing profit momentum driven by product launches. Aging demographics favour ABT. They don't suffer US drug pricing issues, either. They've increased their dividend for the last 47 years.
TOP PICK
TOP PICK
September 12, 2019
Diversified healthcare company, a space she likes. Not impacted by focus on drug pricing. Sell generics to emerging markets. Also a nutritional business and medical devices, which are growing. Has increased dividend 46-47 years in a row. Yield is 1.50%. (Analysts’ price target is $92.87)
Show full opinionHide full opinion
Abbott Labs (ABT-N)
September 12, 2019
Diversified healthcare company, a space she likes. Not impacted by focus on drug pricing. Sell generics to emerging markets. Also a nutritional business and medical devices, which are growing. Has increased dividend 46-47 years in a row. Yield is 1.50%. (Analysts’ price target is $92.87)
WATCH
WATCH
August 22, 2019
They spun off Abvee that produces Humeria that represents 60% of ABT-T. It was the most successful drug in the world. The area they made acquisitions in have been successful. It is a well managed company. It is not inexpensive. 25 times earnings. When something rises like this then if the earnings don't keep up, the multiples goes up. It is a high valuation stock so be cautious.
Show full opinionHide full opinion
Abbott Labs (ABT-N)
August 22, 2019
They spun off Abvee that produces Humeria that represents 60% of ABT-T. It was the most successful drug in the world. The area they made acquisitions in have been successful. It is a well managed company. It is not inexpensive. 25 times earnings. When something rises like this then if the earnings don't keep up, the multiples goes up. It is a high valuation stock so be cautious.
DON'T BUY
DON'T BUY
August 13, 2019

The PFE-N non-patent drugs will be dilutive for earnings in the short term. She prefers either JNJ-N or ABT-N

Show full opinionHide full opinion
Abbott Labs (ABT-N)
August 13, 2019

The PFE-N non-patent drugs will be dilutive for earnings in the short term. She prefers either JNJ-N or ABT-N

BUY WEAKNESS
BUY WEAKNESS
July 10, 2019
Healthcare has had a good run. They have medical devices and are diversified globally. Don't chase it.
Show full opinionHide full opinion
Abbott Labs (ABT-N)
July 10, 2019
Healthcare has had a good run. They have medical devices and are diversified globally. Don't chase it.
BUY
BUY
May 30, 2019
It is a very fine company. They have increased dividends for about 45 years in succession. They are very predictable. They spun off their pharmaceutical division in 2013. They reinvented themselves by buying a heart medication company, a diagnostic company and a strong nutrition business.
Show full opinionHide full opinion
Abbott Labs (ABT-N)
May 30, 2019
It is a very fine company. They have increased dividends for about 45 years in succession. They are very predictable. They spun off their pharmaceutical division in 2013. They reinvented themselves by buying a heart medication company, a diagnostic company and a strong nutrition business.
TOP PICK
TOP PICK
May 14, 2019
A diversified healthcare company. Their medical devices and diagnostic division is doing quite well with many new products. Pays a good dividend of 1.7% that they have increased for past decades. She likes this space. ABT has good growth. (Analysts’ price target is $83.05)
Show full opinionHide full opinion
Abbott Labs (ABT-N)
May 14, 2019
A diversified healthcare company. Their medical devices and diagnostic division is doing quite well with many new products. Pays a good dividend of 1.7% that they have increased for past decades. She likes this space. ABT has good growth. (Analysts’ price target is $83.05)
BUY
BUY
February 11, 2019
They are a core holding in the medical area. They have done well recently. They will not make a home run because they make commodities. They are big and they dominate the business. As hospital spending picks up they will get their share. You will get more upside from other companies if their drugs come through. He would not hesitate to own ABT-N. It is slow and steady.
Show full opinionHide full opinion
Abbott Labs (ABT-N)
February 11, 2019
They are a core holding in the medical area. They have done well recently. They will not make a home run because they make commodities. They are big and they dominate the business. As hospital spending picks up they will get their share. You will get more upside from other companies if their drugs come through. He would not hesitate to own ABT-N. It is slow and steady.
COMMENT
COMMENT
February 6, 2019
A great company, but he would prefer to take a basket approach. High-quality and good capital deployment. He likes the medical equipment space. He would prefer to hold the ETF IHI-N instead.
Show full opinionHide full opinion
Abbott Labs (ABT-N)
February 6, 2019
A great company, but he would prefer to take a basket approach. High-quality and good capital deployment. He likes the medical equipment space. He would prefer to hold the ETF IHI-N instead.
BUY
BUY
January 23, 2019
Likes healthcare and ABT. It's moving higher. 1.8% dividend. Hold it. Fair valuation.
Show full opinionHide full opinion
Abbott Labs (ABT-N)
January 23, 2019
Likes healthcare and ABT. It's moving higher. 1.8% dividend. Hold it. Fair valuation.
TOP PICK
TOP PICK
January 10, 2019
They owned for a number of years. 35% of their business is in the US and 40% emerging markets. Well diversified. They have four divisions: nutritionals, established pharmaceuticals, generics and medical devices and diagnostics. She sees double digit growth in earnings. (Analysts’ price target is $78.57)
Show full opinionHide full opinion
Abbott Labs (ABT-N)
January 10, 2019
They owned for a number of years. 35% of their business is in the US and 40% emerging markets. Well diversified. They have four divisions: nutritionals, established pharmaceuticals, generics and medical devices and diagnostics. She sees double digit growth in earnings. (Analysts’ price target is $78.57)
BUY WEAKNESS
BUY WEAKNESS
August 23, 2018

Generally, don’t like to buy stocks when they hit all-time highs. He would wait for a better entry point. Great company. Not cheap but the multiple is not that extreme. (Analysts’ price target is $70.81)

Show full opinionHide full opinion
Abbott Labs (ABT-N)
August 23, 2018

Generally, don’t like to buy stocks when they hit all-time highs. He would wait for a better entry point. Great company. Not cheap but the multiple is not that extreme. (Analysts’ price target is $70.81)

BUY
BUY
May 8, 2018

Their medical devices doing well as are their nutritional products given strong global demand; it's diversified and well-managed; pays over 2% dividend with growth. These are products we all need, and with an aging population, there will always be demand.

Show full opinionHide full opinion

Their medical devices doing well as are their nutritional products given strong global demand; it's diversified and well-managed; pays over 2% dividend with growth. These are products we all need, and with an aging population, there will always be demand.

PAST TOP PICK
PAST TOP PICK
April 11, 2018

(A Top Pick May 17/17 Up 38%). He has been very happy with this. It has devices, diagnostics and pharma. The secular trends are positive with aging and obesity adding tailwinds. Their June acquisition was very accretive.

Show full opinionHide full opinion
Abbott Labs (ABT-N)
April 11, 2018

(A Top Pick May 17/17 Up 38%). He has been very happy with this. It has devices, diagnostics and pharma. The secular trends are positive with aging and obesity adding tailwinds. Their June acquisition was very accretive.

PAST TOP PICK
PAST TOP PICK
October 10, 2017

(A Top Pick May 17/17. Up 28%.) He likes that this isn’t a “one trick pony”. It has devices, diagnostics, nutrition, etc. A broad, diversified franchise, in a sector he approves of. Thinks it continues to make a lot of sense.

Show full opinionHide full opinion
Abbott Labs (ABT-N)
October 10, 2017

(A Top Pick May 17/17. Up 28%.) He likes that this isn’t a “one trick pony”. It has devices, diagnostics, nutrition, etc. A broad, diversified franchise, in a sector he approves of. Thinks it continues to make a lot of sense.

Showing 1 to 15 of 120 entries

Abbott Labs(ABT-N) Rating

Ranking : 3 out of 5

Bullish - Buy Signals / Votes : 3

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 1

Total Signals / Votes : 4

Stockchase rating for Abbott Labs is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Abbott Labs(ABT-N) Frequently Asked Questions

What is Abbott Labs stock symbol?

Abbott Labs is a American stock, trading under the symbol ABT-N on the New York Stock Exchange (ABT). It is usually referred to as NYSE:ABT or ABT-N

Is Abbott Labs a buy or a sell?

In the last year, 4 stock analysts published opinions about ABT-N. 3 analysts recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is PAST TOP PICK. Read the latest stock experts' ratings for Abbott Labs.

Is Abbott Labs a good investment or a top pick?

Abbott Labs was recommended as a Top Pick by Christine Poole on 2020-01-14. Read the latest stock experts ratings for Abbott Labs.

Why is Abbott Labs stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Abbott Labs worth watching?

4 stock analysts on Stockchase covered Abbott Labs In the last year. It is a trending stock that is worth watching.

What is Abbott Labs stock price?

On 2020-04-08, Abbott Labs (ABT-N) stock closed at a price of $84.95.